HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Multiple myeloma associated with phenytoin (diphenylhydantoin) therapy].

Abstract
The occurrence of multiple myeloma is described in a patient receiving phenytoin (diphenylhydantoin) for 43 years. In this article, five cases of multiple myeloma and one of immunoblastic lymphadenopathy associated with diclonal gammopathy diagnosed after longterm phenytoin therapy are reviewed. These cases are characterized by lymphadenopathy, hepatosplenomegaly, and no or equivocal bone lesions, which are quite unusual in multiple myeloma. Because of the association of lymphomas with phenytoin, the role of the drug in the etiology of multiple myeloma or plasma cell dyscrasias is still in controversy, but highly suspected. It is suggested that a periodic examination of patients receiving phenytoin may be useful in an early detection of M-component. The possibility of reversing multiple myeloma by removal of phenytoin early in the course of the disease should be investigated.
AuthorsT Kanoh, H Dobashi, T Inada
Journal[Rinsho ketsueki] The Japanese journal of clinical hematology (Rinsho Ketsueki) Vol. 37 Issue 3 Pg. 239-43 (Mar 1996) ISSN: 0485-1439 [Print] Japan
PMID8727349 (Publication Type: Case Reports, English Abstract, Journal Article, Review)
Chemical References
  • Anticonvulsants
  • Phenytoin
Topics
  • Aged
  • Anticonvulsants (adverse effects)
  • Humans
  • Male
  • Multiple Myeloma (chemically induced, pathology)
  • Phenytoin (adverse effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: